NCT04528667View on ClinicalTrials.gov

Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19

PHASE2CompletedINTERVENTIONAL

Enrollment

396

Participants

Timeline

Start Date

January 6, 2021

Primary Completion Date

August 23, 2021

Study Completion Date

October 7, 2021

Conditions

Covid19

Interventions

DRUG

STI-5656

STI-5656 (abivertinib maleate) is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor.

DRUG

Placebo

Placebo capsules

Trial Locations (1)

Unknown

Hospital e Maternidade Christovão da Gama, Santo André

All Listed Sponsors

lead

Sorrento Therapeutics, Inc.

INDUSTRY

NCT04528667 - Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19 | Biotech Hunter | Biotech Hunter